Brokers Offer Predictions for GPCR Q1 Earnings

Key Points

• HC Wainwright expects a Q1 2027 loss of $0.58 per share for Structure Therapeutics and forecasts a Q2 loss of $0.59; the firm maintains a Buy rating.
• The company’s latest reported quarterly loss of $0.66 per share was wider than analysts’ $0.51 estimate. Shares were down 5.3% and opened at $19.84, near their 52-week low of $18.70.
• Analysts’ consensus rating is Moderate Buy, with a consensus price target of $110.91; institutional investors own 91.78% of the shares.

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) - HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for Structure Therapeutics in a research report issued on Thursday, November 12th. HC Wainwright analyst A. Ghosh expects that the company will earn ($0.58) per share for the quarter. HC Wainwright currently has a "Buy" rating on the stock. The consensus estimate for Structure Therapeutics' current full-year earnings is ($2.05) per share. HC Wainwright also issued estimates for Structure Therapeutics' Q2 2027 earnings at ($0.59) EPS.

GPCR has been the subject of several other reports. Citizens Jmp reiterated a "market outperform" rating and issued a $110.00 target price on shares of Structure Therapeutics in a report on Wednesday, September 9th. Canaccord Genuity Group set a $111.00 price target on shares of Structure Therapeutics in a report on Friday, August 7th. Weiss Ratings upgraded shares of Structure Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Wednesday, November 4th. Wall Street Zen downgraded shares of Structure Therapeutics from a "sell" rating to a "strong sell" rating in a research report on Saturday, October 3rd. Finally, Citigroup reaffirmed a "market outperform" rating on shares of Structure Therapeutics in a research note on Friday, August 7th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $110.91.

Structure Therapeutics Trading Down 5.3%

NASDAQ GPCR opened at $19.84 on Friday. Structure Therapeutics has a 1 year low of $18.70 and a 1 year high of $94.90. The company has a market cap of $1.38 billion, a PE ratio of -15.38 and a beta of -1.12. The stock's 50-day moving average price is $28.43 and its two-hundred day moving average price is $46.40.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its quarterly earnings results on Monday, November 9th. The company reported ($0.66) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.15).

Institutional Investors Weigh In On Structure Therapeutics

Several hedge funds have recently bought and sold shares of the business. Squarepoint Ops LLC grew its stake in Structure Therapeutics by 454.5% during the 2nd quarter. Squarepoint Ops LLC now owns 125,575 shares of the company's stock valued at $6,740,000 after acquiring an additional 102,929 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of Structure Therapeutics by 1.6% in the 2nd quarter. Wellington Management Group LLP now owns 7,379,433 shares of the company's stock valued at $396,054,000 after purchasing an additional 119,146 shares during the period. Orbimed Advisors LLC lifted its position in shares of Structure Therapeutics by 27.0% in the first quarter. Orbimed Advisors LLC now owns 1,475,403 shares of the company's stock worth $71,114,000 after purchasing an additional 313,600 shares in the last quarter. Handelsbanken Fonder AB purchased a new stake in shares of Structure Therapeutics in the second quarter worth approximately $1,041,000. Finally, SEB Asset Management AB purchased a new stake in shares of Structure Therapeutics in the first quarter worth approximately $11,811,000. 91.78% of the stock is owned by hedge funds and other institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics is a clinical-stage biopharmaceutical company developing medicines for metabolic and other chronic diseases. Its research approach uses structural biology and computational methods to identify and design small-molecule drug candidates. The company's pipeline includes aleniglipron, an oral small-molecule GLP-1 receptor agonist being developed for obesity and related metabolic conditions. Structure Therapeutics is also advancing other drug candidates targeting biological pathways associated with metabolic disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.